NT 201

DRUG13 trials

Sponsors

Merz Pharmaceuticals GmbH, Merz Aesthetics GmbH, Merz North America, Inc.

Conditions

Acetylcholine Release InhibitorsBlepharospasmBotulinum Toxins, Type ACerebral PalsyCervical DystoniaCholinergic AgentsChronic Troublesome SialorrheaEnlarged Pores

Phase 1

A Study of NT 201 in the Treatment of Enlarged Pores and Excessive Sebum Production in the Face

CompletedNCT05784363

Merz North America, Inc.Enlarged Pores, Sebum Production

Start: 2022-10-27End: 2024-07-31Updated: 2024-08-23

Phase 2

Blepharospasm Short Interval

TerminatedNCT00507637

Merz Pharmaceuticals GmbHBlepharospasm

Start: 2007-08-31End: 2008-02-29Updated: 2012-02-06

Study to Investigate the Safety and Duration of Effect of Different Botulinum Toxin A (NT 201) Dose Groups Following the Treatment of Glabellar Frown Lines

CompletedNCT03806933

Merz Aesthetics GmbHModerate to Severe Glabellar Frown Lines

Start: 2019-01-23End: 2020-10-08Updated: 2023-11-15

A Study to Investigate the Efficacy and Safety of NT 201 (Botulinum Toxin) Compared With Placebo for the Treatment of Adult Participants With Essential Tremor in the Arm

CompletedNCT04766723

Merz Pharmaceuticals GmbHEssential Tremor of the Upper Limb

Start: 2021-02-24End: 2023-11-21Updated: 2026-05-28

A Study of NT 201 Doses in the Treatment of Platysma Prominence

CompletedNCT05773053

Merz Aesthetics GmbHPlatysma Prominence

Start: 2023-03-22End: 2024-01-24Updated: 2024-10-21

Phase 3

Safety and Efficacy of NT 201, Free of Complexing Proteins, in the Treatment of Glabellar Frown Lines

CompletedNCT00694148

Merz Pharmaceuticals GmbHHealthy

Start: 2008-05-31End: 2009-01-31Updated: 2012-10-30

Clinical Study to Investigate the Efficacy and Safety of NT 201 Compared to Placebo in the Treatment of Chronic Troublesome Drooling Associated With Neurological Disorders and/or Intellectual Disability

CompletedNCT02270736

Merz Pharmaceuticals GmbHCerebral Palsy, Chronic Troublesome Sialorrhea, Intellectual Disability +2

Start: 2015-02-09End: 2019-05-07Updated: 2021-08-10

Study to Compare the Efficacy and Safety of NT 201 (Botulinum Toxin) With Placebo for the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury

Active, not recruitingNCT03992404

Merz Pharmaceuticals GmbHLower Limb or Combined Lower Limb and Upper Limb Spasticity Due to Stroke or Traumatic Brain Injury

Start: 2019-09-16End: 2027-04-01Updated: 2026-08-21

Safety and Efficacy Study of the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines and Lateral Canthal Lines) in Subjects With Moderate to Severe Upper Facial Lines

CompletedNCT04594213

Merz North America, Inc.Moderate to Severe Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines, and Lateral Canthal Lines)

Start: 2020-09-23End: 2022-05-09Updated: 2024-05-08

Safety and Efficacy Study of the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines and Crows Feet) in Subjects With Moderate to Severe Upper Facial Lines

CompletedNCT04622254

Merz North America, Inc.Moderate to Severe Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines, and Lateral Canthal Lines)

Start: 2020-11-12End: 2022-07-08Updated: 2024-08-06

A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in the United States

Active, not recruitingNCT07122193

Merz North America, Inc.Acetylcholine Release Inhibitors, Botulinum Toxins, Type A, Cholinergic Agents +7

Start: 2025-08-27End: 2027-09-01Updated: 2026-09-10

A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in Europe (PLATINUM EU)

Active, not recruitingNCT07210463

Merz Aesthetics GmbHAcetylcholine Release Inhibitors, Botulinum Toxins, Type A, Cholinergic Agents +7

Start: 2025-10-01End: 2027-08-01Updated: 2026-09-10

Phase 4

Daily Dystonia Practice - A Trial to Investigate NT 201, the Duration of Treatment Effect After One Injection Session and in Long-term Treatment in Cervical Dystonia

CompletedNCT00541905

Merz Pharmaceuticals GmbHCervical Dystonia

Start: 2007-09-30End: 2010-05-31Updated: 2013-06-04

Related Papers

Aesthetic Improvements Over Time: Long‐Term Efficacy and Additional Outcomes of IncobotulinumtoxinA in the Simultaneous Treatment of Upper Facial Lines

Journal of Cosmetic Dermatology2025-09-01

IncobotulinumtoxinA in the Treatment of Upper Facial Lines: Results From Two Randomized, Double-Blind, Placebo-Controlled, Phase III Studies

Aesthetic Surgery Journal2024-10-304 citations

Placebo-Controlled Clinical Trial of IncobotulinumtoxinA for Sialorrhea in Children: SIPEXI.

2021-10-0419 citations